Disease modifying therapies in heart failure: an update

Area of Science:

• Cardiology
• Pharmacology
• Internal Medicine

Background:

• Limited evidence-based disease-modifying pharmacotherapy exists for heart failure with mildly reduced/preserved ejection fraction (HFmrEF/HFpEF).
• This represents a significant unmet clinical need in current heart failure management.
• Existing treatments primarily focus on symptom management rather than addressing underlying disease progression in this cohort.

Purpose of the Study:

• To discuss the potential roles of emerging pharmacotherapies in treating HFmrEF/HFpEF.
• To propose an updated pharmacological strategy for patients with HFmrEF/HFpEF based on recent clinical trial findings.
• To address the unmet clinical need for effective disease-modifying treatments in this patient group.

Main Methods:

• Review of recent clinical trial data on specific medications.
• Analysis of the efficacy and safety profiles of finerenone and glucagon-like peptide-1 receptor agonists in HFmrEF/HFpEF populations.
• Synthesis of evidence to formulate a proposed pharmacological strategy.

Main Results:

• Recent clinical trials indicate promising results for finerenone and glucagon-like peptide-1 receptor agonists in HFmrEF/HFpEF.
• These medications demonstrate potential for disease modification beyond traditional therapies.
• Evidence suggests these agents can improve clinical outcomes in HFmrEF/HFpEF patients.

Conclusions:

• Finerenone and GLP-1 receptor agonists represent a new frontier in HFmrEF/HFpEF pharmacotherapy.
• An updated pharmacological strategy incorporating these agents is proposed for improved patient care.
• These advancements offer hope for better management of heart failure with preserved and mildly reduced ejection fraction.